Prosecution Insights
Prosecution Insights
Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Shanghai Sinorda Biomedicine Co. Ltd. maintains a patent portfolio in the Biotechnology & Pharmaceuticals technology area. Currently, the company has 1 pending office action. This action is being reviewed by 1 distinct examiner, showing a singular focus in the company's current prosecution efforts. The portfolio's active prosecution is limited to 1 distinct art unit.
DAVIS, BRIAN J is the busiest examiner for the company, currently managing 1 pending office action. Since the total number of pending office actions is 1, this examiner is the only one currently interacting with the company's filings. Practitioners should recognize that the company's immediate progress in the Biotechnology & Pharmaceuticals sector is tied to this single pending matter. The concentration in 1 distinct art unit and the involvement of only 1 distinct examiner, DAVIS, BRIAN J, suggests a very specific technical focus.
Prosecution strategy can be highly customized to the individual examiner's past behavior and the specific standards of the single art unit involved. The presence of 1 pending office action indicates a low volume of active conflict at the patent office, allowing for a concentrated legal effort on this specific application. The progress of the company's current filings is tied to the specific examination patterns of DAVIS, BRIAN J, who manages 1 pending office action. This concentration in 1 distinct art unit minimizes the complexity of the company's current patent office engagements.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §112 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| DAVIS, BRIAN J | 1 | 84.8% | -4.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18851965 | X842 FORMULATION | DAVIS, BRIAN J | — |
| Art Unit | Apps |
|---|---|
| 1614 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18851965 | X842 FORMULATION | DAVIS, BRIAN J | 1614 | §112 | Non-Final OA | — | Pending | Sep 27, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial